白介素-2联用短化治疗50例伴发乙肝初治涂阳肺结核疗效观察  

The observation of curative effect of IL-2 supplemented with short-course chemotherapy for 50 cases of smear-positive pulmonary tuberculosls accompanying hepatitis B

作　　者：朱杰 施南峰 岑隆根 

机构地区：[1]浙江省慈溪市卫生防疫站,315300

出　　处：《中国防痨杂志》2000年第4期222-224,共3页Chinese Journal of Antituberculosis

摘　　要：目的　提高伴发乙肝初治涂阳肺结核治疗疗效 ,减少副作用产生。方法　采用IL 2联用2SHRZ/ 4H3R3方案治疗 50例伴发乙肝初治涂阳肺结核 ,并以同期用 2SHRZ/ 4H3R3和一般护肝药治疗2 3例作为对照。结果　治疗 6月末IL 2组痰菌阴转率、HBeAg和HBV DNA的转阴率分别为 96.0 %、70 .4 %和 71.4 % ,明显高于对照组的 65.3%、8.3%和 14.3% (P <0 .0 1) ,并且前者肝功损害发生率和停药率均为 0 ,要明显低于后者的 2 6.1% (P <0 .0 1) ,2年随访IL 2组痰菌复发率、HBeAg和HBV DNA的转阴率分为 0、10 .5%和 10 .0 % ,与对照组 6.7%、0和 50 .0 %无明显差别 (P <0 .0 5)。结论　IL 2有较好抗痨、抑制乙肝病毒复制和间接改善肝脏病变 ,降低抗痨药物肝功损害作用 ,值得临床进一步探讨。Objective To improve the curative effect and reduce side effect in the treatment of smear-positive pulmonary tuberculosis accompanying hepatitis B.Methods Use Interleukin-2(IL-2) in a daily dose of 20 000 U supplemented with 2SHRZ/4H 3R 3 for 50 patients and contrast with 23 patients treated by 2SHRZ/4H 3R 3 and ordinary liver-curing medicine.Results The sputum negative conversion rates,HBeAg and HBV-DNA from positive to negative of the active group after 6 months themotherapy were 96.0%,70.4% and 71.4% respectively,which is obviously higher than 65.3%,8.3%and 14.3% of the control group ( P <0.01).In the meantime,both the hepatic damage rate and drug withdrawal rate of the former were 0,Which is also obviously lower than the latter 26.1%( P <0.01),the recurrence rate of sputum,the conversion rates of HBeAg and HBV-DNA from positive to negative of the active group were 0,10.5% and 10.0% and the rates of control group were 6.7%,0,50.5% respectively according to a two-year follow-up examination,which indicatng less difference between active and control groups.Conclusion IL-2 is effective in antituberculosis,inhibit of reproduction of hepatitis B virus,as well as in reliving liver pathological process and reducing hepatic damage by antituberculous drugs.

关 键 词：结核 肺 乙型肝炎 白介素-2 

分 类 号：R521.06[医药卫生—内科学] R512.620.5[医药卫生—临床医学]